Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Phase 1
Suspended
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Unresectable Fibrolamellar Carcinoma
- Interventions
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04380545
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
Not Applicable
Recruiting
- Conditions
- Glioma
- Interventions
- Procedure: Magnetic Resonance ElastographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT04373720
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
Phase 2
Terminated
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- Biological: Tagraxofusp-erzs
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04317781
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
Phase 2
Terminated
- Conditions
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- Drug: DabrafenibBiological: SpartalizumabProcedure: Therapeutic Conventional SurgeryDrug: Trametinib
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04310397
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy
Not Applicable
Active, not recruiting
- Conditions
- Ovarian Carcinoma
- Interventions
- Dietary Supplement: Dietary InterventionOther: Media InterventionBehavioral: Telephone-Based Intervention
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT04310826
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ventilatory Strategy for the Prevention of Atelectasis During Bronchoscopy Under General Anesthesia, VESPA Trial
Not Applicable
Completed
- Conditions
- Lung Disorder
- Interventions
- Procedure: Anesthesia ProcedureProcedure: Bronchoscopy
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT04311723
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
Phase 4
Active, not recruiting
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 84
- Registration Number
- NCT04296305
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam
Active, not recruiting
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Other: Hyperpolarized Carbon C 13 PyruvateProcedure: Magnetic Resonance Spectroscopic ImagingProcedure: Surgical Procedure
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 130
- Registration Number
- NCT04286386
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
Not Applicable
Active, not recruiting
- Conditions
- Lymphoma
- Interventions
- Other: Educational InterventionOther: Meditation TherapyOther: Questionnaire Administration
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 71
- Registration Number
- NCT04270266
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women
Not Applicable
Recruiting
- Conditions
- Breast Carcinoma
- Interventions
- Other: Aerobic ExerciseOther: Dietary InterventionOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationOther: Resistance Training
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT04267796
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath